Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

trialsTrialRecruiting

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

A phase 1/2 trial of R906289 Monosodium (R289 Na) in myelodysplastic syndromes / neoplasms, run by Rigel Pharmaceuticals, now recruiting.

Overview Connected3

Overview

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) is a phase 1/2 interventional study registered as NCT05308264 by Rigel Pharmaceuticals, with 86 participants planned, started 2022-09-12 and due to reach its primary completion in 2026-08. Interventions recorded: R906289 Monosodium (R289 Na).

Setting

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

Phase

Phase 1/2

Sponsor

Rigel Pharmaceuticals

Registry

Started

2022-09-12

Enrolled

86 enrolled

Connected

Similar pages

Trial
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Shares Lower-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Trial
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Shares Lower-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Trial
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Trial
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Trial
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Trial
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Trial
PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Trial
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.

cancers

Lower-risk myelodysplastic syndromes Myelodysplastic syndromes / neoplasms (MDS)

companies

Rigel Pharmaceuticals

Evidence strength18/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
86 enrolled+10
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Blood cancers by driver, state and phase · diff · file

Sources & links

ClinicalTrials.gov NCT05308264

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Myelodysplastic syndromes / neoplasms (MDS)
Lower-risk myelodysplastic syndromes

Companies

Rigel Pharmaceuticals

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct05308264/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct05308264.

WebMCP tools registered on this page: onco_search, onco_get_entity.